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ABSTRACT 
Background: Breast cancer symptoms are often not felt clearly by patients, as a result many patients who come 
in an advanced stage. This will affect the prognosis and cure rate of the patient. There are several factors that 
influence the prognosis of breast cancer, including histopathological grade, and classic immunohistochemical 
markers such as estrogen receptors, progesterone receptors, and HER2. In addition, breast cancer can be 4 main 
molecular subtypes, namely Luminal A, Luminal B, HER2-Overexpression, and Triple Negative / Basal-Like. 
Objectives: This study aims to determine the relationship between histopathological grade with the molecular 
subtypes of breast cancer patients in Haji Adam Malik General Hospital in 2016-2018. Methods: This is analytical 
cross-sectional research using a consecutive-sampling technique. Data were obtained secondary from the medical 
records of breast cancer patients at Haji Adam Malik General Hospital in 2016-2018 and then analyzed with the 
chi-square test. From 1005 cases of breast cancer during the 2016-2018 period, 131 samples were taken in this 
study. Results: Of the 131 samples, the highest histopathological grade was grade 2 with 53 people  (40.5%), 
followed by 41 people (31.3%) with grade 3, and 37 people (28.2%) with grade 1. The most molecular subtypes 
were Luminal A with 38 people (29%), followed by 33 people (25.2%) with Luminal B, 31 people (23.7%) with 
HER-2 Overexpression, and 29 people (22.1%) with Triple Negative / Basal-like. From the analysis of the chi-
square test obtained p value of 0.045. Conclusion: There is a relationship between histopathological grade with 
molecular subtypes of breast cancer patients. 
Keywords: breast cancer, histopathological grade, immunohistochemistry, molecular subtypes  
 
ABSTRAK 
Latar Belakang: Gejala-gejala kanker payudara sering tidak dirasakan dengan jelas oleh pasien, akibatnya 
banyak pasien yang datang dalam keadaan stadium lanjut. Hal ini akan mempengaruhi prognosis dan tingkat 
kesembuhan pasien. Terdapat beberapa faktor yang mempengaruhi prognosis dari kanker payudara, antara lain 
grading histopatologi, dan marker imunohistokimia klasik seperti reseptor estrogen, reseptor progesteron, dan 
HER2. Selain itu, kanker payudara dapat diklasifikasikan menjadi 4 subtipe molekuler utama, yaitu Luminal A, 
Luminal B, HER2-Overexpression, dan Triple Negative/Basal-Like. Tujuan: Penelitian ini bertujuan untuk 
mengetahui hubungan antara grading histopatologi dengan subtipe molekuler pasien kanker payudara di RSUP 
Haji Adam Malik Tahun 2016-2018. Metode: Penelitian ini merupakan penelitian analitik menggunakan desain 
cross-sectional dengan teknik pengambilan sampel consecutive-sampling. Data diperoleh secara sekunder dari 
rekam medis pasien kanker payudara di RSUP Haji Adam Malik pada tahun 2016-2018 dan kemudian dianalisis 
dengan uji chi-square. Dari 1005 kasus kanker payudara selama periode 2016-2018, diambil sampel pada 
penelitian ini sebanyak 131 buah rekam medis. Hasil: Dari 131 sampel, grading histopatologi terbanyak terdapat 
pada grade 2 dengan 53 orang (40,5%) , diikuti 41 orang (31,3%) dengan grade 3, dan 37 orang (28,2%) dengan 
grade 1. Subtipe molekuler terbanyak yaitu Luminal A dengan 38 orang (29%), diikuti 33 orang (25,2%) dengan 
Luminal B, 31 orang (23,7%) dengan HER-2 Overexpression, dan 29 orang (22,1%) dengan Triple 
Negative/Basal-like. Dari hasil uji chi-square diperoleh nilai p sebesar 0,045. Kesimpulan: Terdapat hubungan 
antara grading histopatologi dengan subtipe molekuler pasien kanker payudara. 
Kata kunci: grading histopatologi, imunohistokimia, kanker payudara, subtipe molekuler 
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Cancer is a condition that occurs when 
abnormal cells grow in a way that is not 
controlled and can damage the surrounding 
tissue or spread to other parts of the body.[1] 
One type of cancer that is frightening for all 
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Breast cancer is a type of cancer with the 
highest incidence along with lung cancer in 
2.09 million cases followed by colorectal 
cancer (1.8 million), prostate (1.28 
million), skin (1.04 million), and stomach 
(1.03 million). Breast cancer is the most 
common type of cancer among women in 
the world with a mortality rate reaching 
627,000 women in 2018.[3] In Indonesia, the 
incidence of breast cancer in 2019 reached 
42.1 per 100,000 population with an 
average death rate of 17 per 100.000 
population.[4] Meanwhile, North Sumatra 
ranks seventh in Indonesia with an 
incidence rate of 0.4 per 100,000 
population.[5] 
Breast cancer symptoms are often not 
felt clearly by the patient and, as a result, 
many patients seek treatment when the 
disease is already in an advanced stage 
(stage III and IV). This is according to data 
from Dharmais Cancer Hospital medical 
records in 2010 showed that around 85% of 
breast cancer patients were already at an 
advanced stage when they came to the 
hospital. This will affect the prognosis and 
cure rate of the patient.[6,7] Factors that 
influence the prognosis of breast cancer are 
divided into two groups, major and minor 
prognostic factors. Major prognostic 
factors include: invasive or in situ cancer, 
lymph node metastases, distant metastases, 
tumor size, advanced local disease, and 
inflammatory cancer. While minor 
prognostic factors consist of: histologic 
subtypes, tumor grading, proliferation rate, 
DNA content and classical 
immunohistochemical (IHC) markers such 
as estrogen receptors (ER), progesterone 
receptors (PR), and human epidermal 
growth factor receptor-2 (HER2).[8,9] 
Tumor histology grading is a tumor 
based on tumor cell abnormalities and 
tumor tissue seen under a microscope. This 
grading is determined based on the 
assessment of tubule/gland formation, 
nucleus pleomorphism and the number of 
mitoses. Determination of tumor histology 
grading using the Patey & Sarff, Blood & 
Richardson method modified by Elston & 
Ellis. Grading is associated with a life 
expectancy of 10 years, namely grade I 
(85%), grade II (60%), and grade III (45%). 
Grade I shows the best prognosis, grade II 
shows a moderate prognosis, while grade 
III shows the worst prognosis.[10,11] 
Breast cancer has different 
histopathological features and biological 
characteristics so that it shows a different 
treatment response and different 
therapeutic strategies must be given as 
well.[12,13] Therefore, breast cancer 
grouping into molecular subtypes is carried 
out to determine the type of treatment that 
is more accurate.[8] According to the St. 
Gallen consensus in 2011, breast cancer can 
be classified into 4 main molecular 
subtypes based on the molecular expression 
of estrogen receptors (ER), progesterone 
receptors (PR), human epidermal receptor 2 
(HER2), and proliferative index (Ki-67), 
namely Luminal A (ER +, PR +, HER2-, 
and Ki-67 ≤14%), Luminal B (ER +, PR +, 
HER2-, and Ki-67> 14%; ER + and/or PR 
+, HER2 +), HER2 + Type (ER-, PR- , and 
HER2 +), and Triple Negative / Basal-Like 
(ER-, PR-, and HER2). [14,15] 
Based on research conducted by 
Kadivar et al. in 2012, there was a 
relationship between molecular subtypes 
and tumor characteristics, such as size, 
grading, and lymphovascular infiltration. 
Luminal A is the most frequent molecular 
subtype, next luminal B, then basal-like and 
finally, type HER2. Basal-like types and 
HER2 generally have grade III, whereas 
luminal A has grade I.[16] According to 
Shomaf et al. in 2013, in HER2 and basal-
like types, the majority of cases were grade 
III tumors, and none of the cases were grade 
I tumors.[17] 
According to research at RSUP Dr. M. 
Djamil Padang, molecular subtypes of 
Triple-Negative were more common in 
grade III which was 52.6%, HER2 occurred 
more in grade I which was 33.3%, Luminal 
B was more common in grade II which was 
36.6% and Luminal A was more common 
in grade I, 33.3%. This proves that 




Relationship of Histopathology Grading with Molecular Subtypes of Breast Cancer Patients  
in Haji Adam Malik General Hospital 2016-2018  
occurrence of molecular subtypes in breast 
cancer patients.[18] 
Research on the relationship of 
histopathological grading with molecular 
subtypes of breast cancer patients has not 
been done much in Indonesia. Based on the 
description above, researchers are 
interested in researching with the title 
Relationship of Histopathology Grading 
with Molecular Subtypes of Breast Cancer 
Patients in Haji Adam Malik General 
Hospital Medan in 2016-2018. 
 
 
This type of research is observational 
analytic with a cross-sectional design to 
look for the relationship between 
independent variables (histopathological 
grading) with the dependent variable 
(molecular subtype) in breast cancer 
patients. This research was conducted at the 
Haji Adam Malik General Hospital in July 
2019 to October 2019. The population in 
this study were all breast cancer patients 
listed in the medical record data at the Haji 
Adam Malik General Hospital in Medan in 
2016-2018. The sample in this study was 
taken with a non-probability sampling 
technique of consecutive sampling type 
where samples that met the selection 
criteria were included in the study until the 
required number of samples was met. From 
1005 cases of breast cancer in the period 
2016-2018, 131 samples that met the 
inclusion and exclusion criteria were taken 
in this study.  
Inclusion criteria in this study were 
patients diagnosed with breast cancer in 
2016-2018, there were grading diagnoses 
on histopathological examination, and there 
were diagnoses of molecular subtypes on 
immunohistochemical examination.  
Data is processed through several 
stages, namely Editing, Coding, Entring, 
Cleaning, and Saving. The data obtained 
were then presented descriptively in 
narrative form, proportion distribution 
tables, and statistical analysis to look for the 
relationship of histopathological grading 
with molecular subtypes in breast cancer 
patients with the Chi-square test in the 
statistical application program. 
 
 
Table 1. Frequency distribution of samples by 
age 




≤ 25 years 2 1.5 
26-35 years 10 7.6 
36-45 years 61 46.6 
46-55 years 31 23.7 
56-65 years 22 16.8 
>66 years 5 3.8 
Total 131 100 
Based on table 1, it is known that from 
131 cases of breast cancer in the Haji Adam 
Malik General Hospital in 2016-2018, the 
majority were in the 36-45 years age group 
of 61 people (46.6%), then followed by the 
46-55 year age group as many as 31 people 
(23.7%), the age group of 56-65 years were 
22 people (16.8%), the age group of 26-35 
years were 10 people (7.6%), the age group 
> 66 years were 5 people (3.8%), and the 
age group ≤ 25 years were 2 people (1.5%). 
The mean age (mean) in this study was 
46.61 years (median = 44 years, SD = 
9.902). 








Grade 1 37 28.2 
Grade 2 53 40.5 
Grade 3 41 31.3 
Total 131 100 
Based on table 2, it can be seen that 
from 131 cases of breast cancer in Haji 
Adam Malik General Hospital 2016-2018, 
the highest grade of histopathology grading 
was grade 2 with 53 people (40.5%), 
followed by grade 3 with 41 people (31, 
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Luminal A 38 29 




TNBC/Basal-like 29 22.1 
Total 131 100 
Based on table 3, it can be seen that 
from 131 cases of breast cancer in Haji 
Adam Malik General Hospital in 2016-
2018, the highest molecular subtypes were 
Luminal A with 38 people (29%), then the 
second was 33 Luminal B subtypes (25 
people), 2%), the third was the HER-2 
Overexpression subtype of 31 people 
(23.7%), and TNBC / Basal-like was the 
molecular subtype with the smallest 
occurrence rate of 29 people (22.1%). 
Table 4 shows that based on 
histopathological grading, Luminal B 
molecular subtypes were more often found 
in grade 1 in 15 cases (11.5%), while grade 
2 was often found in Luminal A molecular 
subtypes in 16 cases (12.2%), HER -2 as 
many as 15 cases (11.5%), and TNBC as 
many as 14 cases (10.7%). The results in 
Table 4 are then performed a chi-square test 
with a significance level of 0.05 (α = 5%), 
the p value obtained is 0.045 (p <0.05) 
which means there is a relationship between 
histopathological grading with molecular 




Table 4. Relationship of histopathological grading with molecular subtypes 
Molecular Subtypes 
Total 
  Luminal A Luminal B HER-2 TNBC   p value 
  N % N % N % N % N %  
 1 13 9.9 15 11.5 6 4.6 3 2.3 37 28.2  
Grade 2 16 12.2 8 6.1 15 11.5 14 10.7 53 40.5 0.045 
 
3 9 6.9 10 7.6 10 7.6 12 9.2 41 31.3 
 
Total  38 29 33 25.2 31 23.7 29 22.1 131 100  
 
 
From the results of this study, the 
majority of breast cancer patients were in 
the age group 36-45 years (46.6%) and at 
least in the age group ≤ 25 years (1.5%). 
The results of this study can be said in 
accordance with research conducted by 
Siadati et al. in 2015 which found that 
breast cancer patients were most prevalent 
in the age group of 35-45 years, as well as 
research conducted by Geethamala et al. in 
2015 which found that the majority of 
patients breast cancer is at the 3rd and 4th 
decade (76%).[19,20] In addition, this study's 
data are consistent with research from the 
American Cancer Society in 2017 which 
states that this disease rarely occurs in 
women younger than 25 years.[21] Age is a 
significant risk factor for breast cancer.[22] 
Currently, the incidence of breast cancer is 
more common in young adult women with 
an age range of < 40 years.[23] This can be 
due to an increase in the world population 
itself, increased awareness of both patients 
and doctors in diagnosing diseases, 
increased case reporting, as well as the role 
of other risk factors such as internal factors 
namely parity at a young age, family history 
of breast cancer or other malignancies, 
mutation of the Breast Cancer 
Susceptibility Gene 1 (BRCA 1) or Breast 
Cancer Susceptibility Gene 2 (BRCA 2), 
p53 mutations, and environmental factors 
such as radiation therapy due to Hodgkin's 
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of hormone replacement therapy, and 
lifestyle (smoking, alcohol consumption, 
rarely exercising). [24] 
In this study, most samples had grade 2 
(40.5%) from the results of the 
histopathological examination on medical 
records. The results of this study are 
consistent with the 2016 study of Firdaus et 
al. in RSUP M. Djamil Padang who found 
that the majority of breast cancer sufferers 
had histopathological grading at grade 2 of 
62.1%, followed by grade 3 at 26.8%, and 
grade 1 at 9.1%.[18] This is also supported 
by the results of 2016 Syukri et al's study 
which also found grade 2 was the most 
common histopathological grading of 
53.8%, followed by grade 3 of 44% and 
grade 1 of 1.8%.[25] Tumor grading is a 
tumor based on the abnormality of tumor 
cells and tumor tissue seen under a 
microscope. Grading is determined based 
on how different tumor cells look from 
normal breast cells, and how fast they grow. 
Grading is assessed using a scoring system 
for 3 tumor characteristics (tubule/gland 
formation, nucleus pleomorphism, number 
of mitoses) and will reflect the 
aggressiveness of tumor cells ie. the higher 
the grade, the more aggressive the tumor. 
Grading is the main prognostic factor that 
must be reported in the results of 
histopathological examination of breast 
cancer. Grading is associated with a life 
expectancy of 10 years, namely grade 1 
(85%), grade 2 (60%), and grade 3 (45%). 
Grade 1 shows the best prognosis, grade 2 
shows a moderate prognosis, while grade 3 
shows the worst prognosis.[10,11,26] 
From the results of the study, it was 
found that the majority of the samples had 
Luminal A molecular subtypes (29%). The 
results of this study are in line with the 
study of Su et al. in 2011 in China which 
found that the most frequent molecular 
subtypes were Luminal A at 48.6%, 
followed by Luminal B at 16.7%, HER-2 
Overexpression at 13.7%, and TNBC- 
Basal-like 12.9%.[27] Luminal A is the most 
abundant molecular subtype in this study. 
This result is supported by several studies 
outside and in Indonesia which stated the 
same thing.[16,28-30] In contrast, the results of 
the 2012 El-Fatemi et al. study in North 
Africa found that the Luminal B subtype 
was more dominant than the other subtypes 
with a percentage of 41.8%.[31] Meanwhile, 
different results were obtained in the 2012 
Ly et al. study in Mali which found that the 
TNBC / Basal-like subtype was the most 
frequent molecular subtype with a 
percentage of 51.5%.[32] Ethnics and genes 
of breast cancer sufferers play a role in 
differences in the number of cases of each 
of these molecular subtypes. In Asia, the 
type A luminal is more common than other 
types, whereas in Africa the type B luminal 
and TNBC / Basal-like type are more often 
found, this type has a worse prognosis than 
luminal A. In addition, different 
proportions of subtypes in the population is 
associated with several risk factors for 
breast cancer such as age, BMI, menopause 
status, family history, parity and duration of 
breastfeeding, [31,33] while this study only 
looked at histopathological grading and the 
patient's lymph node status. The most 
common Luminal A molecular subtypes 
found in this study may be due to several 
risk factors such as high BMI, not 
breastfeeding, and early menarche.[29] In 
addition, the study of Devi et al. in 2012 
also mentioned that influence of multi 
factors (westernization) namely sedentary 
lifestyle and obesity can increase the 
incidence of Luminal A molecular 
subtypes.[33]  
Based on the results of this study, it 
was found that the Luminal B molecular 
subtypes were more often found in grade 1, 
while the Luminal A, HER-2, and TNBC 
molecular subtypes were more often found 
in grade 2. Chi-square test results obtained 
p value = 0.045 which means there is a 
relationship between histopathological 
grading with molecular subtypes in breast 
cancer patients. These results are consistent 
with the study of Salhia et al. in 2011 in 
Egypt and Kadivar et al. in 2012 in Iran 
which stated that there was a relationship 
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molecular subtypes of breast cancer 
patients with p = 0.044 (p < 0.05) and p 
<0.001 (p < 0.05).[16,34] The study of Salhia 
et al. also found the same thing with this 
study that the molecular subtypes of 
Luminal A, HER-2, and TNBC were most 
commonly found in grade 2 with successive 
percentages. namely 78.5%, 86.7%, and 
92.3%.[34] However, the molecular subtype 
Luminal B is more commonly found in 
grade 2 so there are differences with this 
study. Meanwhile, in the study of Kadivar 
et al, it was found that the TNBC molecular 
subtype was mostly found in grade 3 with a 
percentage of 63.5%. The other subtypes, 
namely Luminal A, Luminal B, and HER-2 
are mostly found in grade 2 with 
percentages of 56.7%, 69.7%, and 54% 
respectively.[16] Several studies in 
Indonesia have concluded the hypothesis 
test that is consistent with this study 
although there are differences in the 
proportion of molecular subtypes based on 
histopathological grading. This can be seen 
in the 2016 study of Firdaus et al. in RSUP 
Dr. M. Djamil Padang who stated that there 
was a relationship between 
histopathological grading and molecular 
subtypes of breast cancer patients with a 
value of p = 0.032 (p < 0.05). In that study, 
it was found that TNBC molecular subtypes 
were more common in grade 3, 52.6%, 
HER2 occurred more in grade 1, 33.3%, 
Luminal B occurred more in grade 2, 
36.6%, and Luminal A more common in 
grade 1, which is 33.3%.[18] Meanwhile, a 
study by Setyawati et al. in 2018 in 
Yogyakarta also stated that there was a 
significant relationship between 
histopathological grading with molecular 
subtypes of breast cancer with a value of p 
= 0.013 (p < 0.05) with them finding that 
the Luminal A molecular subtype had the 
highest frequency in grade 1 namely 17.6%, 
Luminal B, HER2, and TNBC were more 
common in grade 3, namely 79.4%, 70.8% 
and 77.8% respectively.[29] 
In several studies, it was found that the 
Luminal A molecular subtype is associated 
with grade 1 which has a good prognosis 
and tends to grow slowly.[16,19,20,28,35-38] 
This is because the Luminal A subtype has 
a high expression of several gene markers 
for well-differentiated tumors such as FOX 
A1, GATA3, and Bcl-2. In contrast, the 
Luminal A subtype has a low EGFR marker 
expression. EGFR marker expression 
indicates a breast tumor has a poor 
prognosis. Meanwhile, ER and PR 
expression in this subtype is an indicator 
that a tumor can respond to hormone 
therapy so that it has a better prognosis.[39] 
In this study Luminal B molecular 
subtypes were most commonly found in 
grade 1, this is different from some studies 
that found that Luminal B molecular 
subtypes had the most high-grade tumors 
(grade 3). These results are related to 
several characteristics of the Luminal B 
subtype, namely the larger tumor size, 
extensive node involvement, and advanced 
tumor stage when compared to the Luminal 
A subtype.[40] Another theory says that 
negative expression of Bcl-2 and positive 
expression of HER-2 in the Luminal B 
subtype is associated with poor prognosis 
and low survival rates.[39] 
Breast cancer with the HER-2 subtype 
has a large percentage of tumors with a 
diameter and tends to grow more 
aggressively.[37] In this study, the most 
HER-2 molecular subtypes were found in 
grade 2. These results are different from 
several studies that found that the most 
HER-2 molecular subtypes occur at high 
grading (grade 3). This result is associated 
with a significant relationship between 
HER-2 / neu expression with high 
histological grading. HER-2 / neu is an 
epidermal growth factor on the cell surface 
that transmits growth signals to the cell 
nucleus. Excessive expression of HER-2 
from its receptors is associated with a poor 
prognosis.[19] In addition, this poor 
prognosis can occur due to differences in 
molecular characteristics with the Luminal 
subtype. The HER-2 subtype has higher 
levels of c-Met, survivin, and EGFR 
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expressions are lower when compared to 
the Luminal subtype.[39]  
Although in this study TNBC subtypes 
were mostly found in grade 2 (10.2%), 
TNBC subtypes had the highest grade 3 
percentage (9.2%) when compared to other 
subtypes. This is in accordance with several 
studies which found that the TNBC subtype 
had a relatively high percentage in grade 3, 
so it had a poor prognosis such as the HER2 
subtype. This is associated with a high 
incidence of p-53 mutations, 
downregulation of retinoblastoma (Rb) and 
increased levels of expression of p-16, 
Glut-1 and CAIX.[36]  
 
 
In this study, the highest 
histopathological grading was grade 2, 
followed by grade 3 and grade 1,while the 
most molecular subtypes were Luminal A 
subtypes, followed by Luminal B, HER-2 
Overexpression, and TNBC / Basal-like. 
Based on histopathological grading, 
Luminal B molecular subtypes were found 
mostly in grade 1, whereas molecular 
subtypes Luminal A, HER-2, and TNBC 
were most commonly found in grade 2. 
Based on the results of the chi-square 
test, it can be concluded that there is a 
relationship between histopathological 
grading and molecular subtypes of breast 
cancer patients in Haji Adam Malik 
General Hospital in 2016-2018.       
 
 
If other researchers will conduct 
research in the same field, it is advisable to 
conduct more in-depth research on the 
relationship of the results of other 
histopathological examinations such as 
lymphatic and vascular metastases to the 
molecular subtypes of breast cancer. In 
addition, to improve accuracy in 
determining the HER-2 Overexpression 
subtype, researchers suggest conducting in-
situ hybridization tests to confirm 
immunohistochemical examination with 
HER-2 2+ scores. 
 
 
[1] Refshauge A. Cancer in Australia an 
Overview 2012. 74th ed. Australian 
Institute of Health and Welfare. 
2012;1-5  
[2] InfoDatin Bulan Peduli Kanker 
Payudara 2016. Jakarta: Kementerian 
Kesehatan RI Pusat Data dan 
Informasi. 2016. p. 11.  
[3] World Health Organization. Cancer 
[Internet]. Geneva: World Health 
Organization; 2018 [cited 2019 Apr 
13]. Available from: 
https://www.who.int/news-
room/fact-sheets/detail/cancer  
[4] Kementerian Kesehatan Republik 
Indonesia. Hari Kanker Sedunia 2019 
[Internet]. Jakarta: Kementerian 
Kesehatan Republik Indonesia; 2019 





[5] Riset Kesehatan Dasar 2013. Badan 
Penelitian dan Pengembangan 
Kesehatan Kementerian Kesehatan 
RI; 2013. 
[6] Dwidayati N. Analisis cure rate 
penderita kanker payudara. J Sains 
dan Teknol. 2012;10(2):141–52. 
[7] Nasdaldy. Jakarta: Dharmais 
Hospital National Cancer Center; 
2011 [cited 2019 Apr 13]. Available 
from: www.dharmais.co.id 
[8] Dai X, Li T, Bai Z, Yang Y, Liu X, 
Zhan J, et al. Breast cancer intrinsic 
subtype classification , clinical use 
and future trends. 2015;5(10):2929–
43. 
[9] Kumar V, Abbas AK, Aster JC, 
editors. Robbins basic pathology. 
10th ed. Philadelphia: Elsevier; 2017. 
p. 739-47. 
[10] Kementerian Kesehatan Republik 










Relationship of Histopathology Grading with Molecular Subtypes of Breast Cancer Patients  
in Haji Adam Malik General Hospital 2016-2018  
Pelayanan Kedokteran Tatalaksana 
Kanker Payudara. 2018;1–111. 
[11] Stevens A, Lowe J, Scott I. Core 
Pathology. 3rd ed. United Kingdom: 
Elsevier; 2009. p. 445-7  
[12] Opdahl S, Hagen AI, Romundstad 
PR, Akslen LA, Haugen OA, Vatten 
LJ, et al. Molecular subtypes, 
histopathological grade and survival 
in a historic cohort of breast cancer 
patients. 2013;140(3):463–73. doi: 
10.1007/s10549-013-2647-2 
[13] Rakha EA, Reis-filho JS, Baehner F, 
Dabbs DJ, Decker T, Eusebi V, et al. 
Breast cancer prognostic classifi 
cation in the molecular era : the role 
of histological grade. Breast Cancer 
Res. 2010;12(207):12. doi: 
10.1186/bcr2607 
[14] Goldhirsch A, Wood WC, Coates AS, 
Gelber RD, Thu B. Strategies for 
subtypes — dealing with the diversity 
of breast cancer : highlights of the St 
Gallen International Expert 
Consensus on the primary therapy of 
early breast cancer 2011. Ann Oncol. 
2011;22:1736–47. doi: 
10.1093/annonc/mdr304 
[15] Lv M, Li B, Mao X, Yao F, Jin F. 
Predictive role of molecular subtypes 
in response to neoadjuvant 
chemotherapy in breast cancer 
patients in Northeast China. Asian 
Pacific J Cancer Prev. 2011;12:2411–
7. 
[16] Kadivar M, Mafi N, Joulaee A, 
Shamshiri A. Breast cancer molecular 
subtypes and associations with 
clinicopathological characteristics in 
iranian women, 2002 – 2011. Asian 
Pacific J Cancer Prev. 
2012;13(5):1881–6. doi: 
10.7314/apjcp.2012.13.5.1881 
[17] Shomaf M, Masad J, Najjar S, Faydi 
D. Distribution of breast cancer 
subtypes among Jordanian women 
and correlation with 
histopathological grade : molecular 
subclassification study. J R Soc Med 
Short Reports. 2013;4(10):1–6. doi: 
10.1177/2042533313490516 
[18] Firdaus VR, Asri A, Khambri D, 
Harahap WA. Hubungan grading 
histopatologi dan infiltrasi 
limfovaskular dengan subtipe 
molekuler pada kanker payudara 
invasif di Bagian Bedah RSUP. Dr. 
M. Djamil Padang. J Kesehat 
Andalas. 2016;5(1):165–72. doi: 
10.25077/jka.v5i1.463 
[19] Siadati S, Sharbatdaran M, 
Nikbakhsh N, Ghaemian N. 
Correlation of ER, PR and HER-
2/Neu with other prognostic factors in 
infiltrating ductal carcinoma of 
breast. Iran J Pathol. 2015;10(3):221–
6.  
[20] Geethamala K, Murthy SV, Vani BR, 
Rao S. Histopathological grade 
versus hormone receptor status in 
breast carcinoma- treasure the past. 
Ijbr. 2015;6(7):466–71. doi: 
10.7439/ijbr.v6i7.2203 
[21] American Cancer Society. Breast 
cancer risk and prevention [Internet]. 
Atlanta: American Cancer Society; 
2017  [cited 2019 Apr 7]. Available 
from: http://www.cancer.org 
[22] Katz J. Breast cancer risk factors 




[23] Gabriel CA, Domchek SM. Breast 
cancer in young women. Breast 
Cancer Res. 2010;12(212):1–10. doi: 
10.1186/bcr2647 
[24] Hartaningsih NM, Sudarsa IW. 
Kanker payudara pada wanita usia 
muda di Bagian Bedah Onkologi 
Rumah Sakit Umum Pusat Sanglah 
Denpasar tahun 2002 – 2012. E-
Journal Medika Udayana. 
2014;3(6):1–14. 
[25] Syukri NA, Fidiawati WA, Tripriadi 
ES. Profil pemeriksaan indeks 
proliferatif Ki-67 pada penderita 




Relationship of Histopathology Grading with Molecular Subtypes of Breast Cancer Patients  
in Haji Adam Malik General Hospital 2016-2018  
Achmad. JOM FK Universitas Riau. 
2016;3(1):1–13. 
[26] ESMO. What is breast cancer ? Let us 
answer some of your questions. Eur 
Soc Med Oncol. 2018;1–55. 
[27] Su Y, Zheng Y, Zheng W, Gu K, 
Chen Z, Li G, et al. Distinct 
distribution and prognostic 
significance of molecular subtypes of 
breast cancer in Chinese women: a 
population-based cohort study. BMC 
Cancer. 2011;11(1):292. doi: 
10.1186/1471-2407-11-292 
[28] Elesawy BH, Abd El Hafez A, 
Shawky AE, Arafa M. 
Immunohistochemistry-based 
subtyping of breast carcinoma in 
Egyptian women: a clinicopathologic 
study on 125 patients. Ann Diagn 
Pathol. 2014;18(1):21–6. doi: 
10.1016/j.anndiagpath.2013.10.005 
[29] Setyawati Y, Rahmawati Y, Widodo 
I, Ghozali A, Purnomosari D. The 
association between molecular 
subtypes of breast cancer with 
histological grade and lymph node 
metastases in Indonesian woman. 
Asian Pacific J Cancer Prev. 
2018;19(5):1263–8. doi: 
10.22034/APJCP.2018.19.5.1263 
[30] Widodo I, Dwianingsih EK, 
Triningsih E, Utoro T. 
Clinicopathological features of 
Indonesian breast cancers with 
different molecular subtypes. 
2014;15(15):6109–13. doi: 
10.7314/apjcp.2014.15.15.6109 
[31] El Fatemi H, Chahbouni S, Jayi S, 
Moumna K, Melhouf MA, Bannani 
A, et al. Luminal B tumors are the 
most frequent molecular subtype in 
breast cancer of North african 
women: an immunohistochemical 
profile study from Morocco. Diagn 
Pathol. 2012;7(1):1–7. doi: 
10.1186/1746-1596-7-170 
[32] Ly M, Antoine M, Dembl AK, Levy 
P, Rodenas A, Tour BA, et al. High 
incidence of triple-negative tumors in 
Sub-saharan Africa: a prospective 
study of breast cancer characteristics 
and risk factors in Malian women 
seen in a Bamako University 
Hospital. Oncol. 2012;83(5):257–63. 
doi: 10.1159/000341541 
[33] Devi CR, Tang TS, Corbex M. 
Incidence and risk factors for breast 
cancer subtypes in three distinct 
South-East Asian ethnic groups: 
Chinese, Malay and natives of 
Sarawak, Malaysia. Int J Cancer. 
2012;131(12):2869–77. doi: 
10.1002/ijc.27527 
[34] Salhia B, Tapia C, Ishak EA, Gaber 
S, Berghuis B, Hussain KH, et al. 
Molecular subtype analysis 
determines the association of 
advanced breast cancer in Egypt with 
favorable biology. BMC Womens 
Health. 2011;11(44):1–9. doi: 
10.1186/1472-6874-11-44 
[35] Ambroise M, Ghosh M, Mallikarjuna 
V, Kurian A. Immunohistochemical 
profile of breast cancer patients at a 
tertiary care hospital in North India. 
Asian Pacific J Cancer Prev. 
2011;12(3):625–9.  
[36] Choi J, Jung WH, Koo JS. 
Metabolism-related proteins are 
differentially expressed according to 
the molecular subtype of invasive 




[37] Errahhali ME, Errahhali ME, 
Ouarzane M, El Harroudi T, Afqir S, 
Bellaoui M. First report on molecular 
breast cancer subtypes and their 
clinico-pathological characteristics in 
Eastern Morocco: series of 2260 
cases. BMC Womens Health. 
2017;17(1):1–11. doi: 
10.1186/s12905-016-0361-z 
[38] Onitilo AA, Engel JM, Greenlee RT, 
Mukesh BN. Breast cancer subtypes 
based on ER/PR and Her2 
expression: comparison of 




Relationship of Histopathology Grading with Molecular Subtypes of Breast Cancer Patients  
in Haji Adam Malik General Hospital 2016-2018  
survival. Clin Med Res. 2009;7(1–
2):4–13. doi: 10.3121/cmr.2009.825 
[39] Tamaki M, Kamio T, Kameoka S, 
Kojimahara N, Nishikawa T. The 
relevance of the intrinsic subtype to 
the clinicopathological features and 
biomarkers in Japanese breast cancer 
patients. World J Surg Oncol. 
2013;11:1–13. doi: 10.1186/1477-
7819-11-293 
[40] Hashmi AA, Aijaz S, Khan SM, 
Mahboob R, Irfan M, Zafar NI, et al. 
Prognostic parameters of luminal A 
and luminal B intrinsic breast cancer 
subtypes of Pakistani patients. World 
J Surg Oncol. 2018;16(1):1–6. doi: 
10.1186/s12957-017-1299-9 
37
